67 results about "D galactosamine" patented technology

The irigenin has protective function on the mouse instant liver hurt induced by D-galactosamine,D-GalN, has protective function on the mouse instant liver hurt induced by CC14, has cure function on big mouse liver fiber caused by composite factors, and high restrain function on the liver cancer cell. Therefore, irigenin can be used to prepare relative medicine.

The invention relates to an application of a novel compound in preparation of liver protection drugs or health care products and further relates to a method for preparing the compound through extraction, separation and purification from Sabia parviflora. The pharmacological research indicates that the novel compound can reduce the content of ALT (alanine aminotransferase) and AST (aspartic transaminase) in serum of a CC14 induced acute liver injury model mouse, a D-galactosamine induced acute liver injury model mouse and an ethanol induced liver injury model mouse, reduce the content of MDA (methylene dioxyamphetamine) in liver tissue and enhance SOD (superoxide dismutase) activity of the liver, has a remarkable protection effect on liver injury and is expected to be developed into new drugs or health care products with the liver protection function.

The invention discloses a novel saponin compound with a liver protection effect. Chemical components of liquorice are symmetrically and deeply researched, a novel triterpene saponin compound is obtained by separating from liquorice root according to spectrum and mass spectrometric data analysis. Pharmacological experiment research indicates that the triterpene saponin compound provided by the invention can be used for remarkably lowering the serum ALT (alanine aminotransferase) and AST (asparate aminotransferase) activities and the hepatic tissue MDA (methylene dioxyamphetamine) content of CC14-caused hepatic injury model mice, alcohol-caused hepatic injury model mice and D-galactosamine-caused hepatic injury model mice, can be used for strengthening the liver SOD (superoxide dismutase) activity, and has an obvious protective effect on hepatic injury; toxicity test research indicates that the novel saponin compound with the liver protection effect does not have remarkable toxicity, and is expected to be developed into a novel medicine or a healthcare product with a liver protection effect.

The invention belongs to the field of traditional Chinese medicine production and relates to an application of Cordyceps sobolifera water extract in preparation of an acute liver injury preventing and treating drug. Based on D-galactosamine / lipopolysaccharide induced acute liver injury model experiments, results prove that the Cordyceps sobolifera water extract can relieve lipid peroxidation and oxidative stress injury of liver cells by reducing transaminase (AST and ALT) and alkaline phosphatase (ALP) in serum, remarkably relieves infiltration of inflammatory factors of the liver and improves liver lesion obviously, meanwhile, the Cordyceps sobolifera water extract can relieve infiltration of neutrophils in the liver, inhibit transcription and expression of related inflammatory mediators, reduce inflammation induced inflammatory factor and NO release and inhibit MAPK (mitogen-activated protein kinases) pathway activation. The Cordyceps sobolifera water extract can be used for preparing the acute liver injury preventing and treating drug and is used for protecting liver function and relieving liver inflammation.

The present invention uncovers that mutations in GALNT3 gene encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T3) cause familial tumoral calcinosis (FTC). Methods and pharmaceutical compositions useful for treating disorders associated with abnormal phosphate metabolism are provided. Specifically, inducers of GalNAc-T3 can be used to treat hyperphosphatemia related disorders such as FTC, and on the other hand, inhibitors of GalNAc-T3 can be used to treat disorders associated with hypophosphatemia, such as hypophosphatemic rickets.

According to the pharmacological study on Houttuynoid B, the inventor discovers that Houttuynoid B has a protective effect on the D-galactosamine (D-GalN) induced mice acute liver injury and the CCl4 induced mice acute liver injury. Thus, the Houttuynoid B can be used for preparing a medicine for preventing and treating liver injury or hepatitis. The application of Houttuynoid B in preparing a medicine for treating liver injury is disclosed for the first time; and since the skeleton type is a brand new one and the activity in treating liver injury is unexpectedly strong, the possibility of any other compound offering any inspiration does not exist, outstanding substantial characteristics are obtained, and an obvious progress is made in resisting liver injury.

The invention provides an application of an anoectochilus roxburghii extract in preparation of drug for preventing and / or treating D-galactosamine-induced acute liver injury of mice and belongs to thetechnical field of medicines. Experiments prove that the anoectochilus roxburghii extract can remarkably improve D-galactosamine-induced acute liver injury symptoms for the first time, the specific performance is that the necrosis areas of liver cells of mice are obviously decreased, inflammatory cell infiltration, ballooning and fatty degeneration of liver cells are alleviated, the lobular structure of liver tends to be regular, and the arrangement of hepatic cords are regular and tidy. In terms of biochemical indexes, the anoectochilus roxburghii extract can obviously reduce the increased activity of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and malondialdehyde due to the D-galactosamine-induced acute liver injury. A foundation is laid for further development and utilization of anoectochilus roxburghii as a natural medicine raw material, in particular as a drug for preventing and / or treating liver diseases.

The inventor discovers that Houttuynoid C has a prevention effect on mice acute liver injury induced by D-galactosamine (D-GalN) and has a prevention effect on mice acute liver injury induced by carbon tetrachloride (CCl4) through a pharmacological study. Therefore, Houttuynoid C can be utilized to prepare the medicines for preventing and treating liver injury or hepatitis. Application of Houttuynoid C in preparation of the medicine for preventing and treating liver injury provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the activity of Houttuynoid E on the treatment effect of liver injury is unexpectedly strong; and the probability that any revelation is provided by other compounds does not existe, Houttuynoid C has the excellent substantive features, and Houttuynoid C obviously has a remarkable progress when being used fo preventing liver injury.

The invention relates to the field of synthesis and application of a bioassay probe for early diagnosis of bacterial infection and in particular relates to synthesis and application of a traced galactosylated near-infrared fluorescent probe which can specifically target various bacteria. A galactosylated compound is prepared by a covalent linkage method by using D-galactosamine hydrochloride and a near-infrared fluorescent dye-indocyanine green as main raw materials, so that the galactosylated compound has a targeted diagnosis effect on bacteria. Experiments prove that the synthesized probe is safe and effective, can quickly reach the bacterially infected parts of living bodies, can serve as an assay probe of various bacterial infections, and has good application prospects. If connected with antibiotics, the probe can target the drugs towards the bacterially infected parts to directly kill the bacteria and reduce toxic and side effects on normal tissues and cells.

The invention discloses a synthesizing method of a fucosylated chondroitin sulfate trisaccharide repeat unit. The synthesizing method takes beta-penta-acetyl glucose, D-galactosamine hydrochloride andL-fucose, which are easy to acquire, as raw materials to synthesize monosaccharide glycosylation precursors, and performing glycosylation reaction twice and a series of protecting group conversion toobtain a target product. Under activity test, a prepared fucosylated chondroitin sulfate trisaccharide presents high anti-inflammatory activity and has a good medical application prospect.

The invention discloses a novel triterpenoid saponin compound with a liver protection effect. By systematically and deeply studying chemical components of liquorice, a new triterpenoid saponin compound is separated from licorice through wave spectrum and mass spectrometric data analysis. The pharmacological experimental study represents that the triterpenoid saponin compound disclosed by the invention is capable of obviously reducing CCl4 induced liver injury model mice, ethanol induced liver injury model mice, D-galactosamine induced liver injury model mice serum ALT (alanine aminotransferase), AST (aspartate amino transferase) activity and liver tissue MDA (methylene dioxyamphetamine) content and enhancing liver SOD (superoxide dismutase) activity, and the compound has an obvious protection effect on the liver injury; the toxicity test study represents that the triterpenoid saponin compound with the liver protection effect, which is disclosed by the invention, has no obvious toxicity, and can be hopefully developed as a novel medicine or healthcare product with liver protection effect.

The invention provides an acute different liver damage inducer and a preparation method and application thereof and belongs to the field of animal model making. The effective components of the acute different liver damage inducer comprise D-galactosamine and lipopolysaccharide and is characterized in that the concentration of the D-galactosamine in the inducer is 50-120mg / mL; the concentration ofthe lipopolysaccharide in the inducer is 0.1-10 microgram / mL; the solvent of the inducer is normal saline. The application of the inducer includes: applying the acute different liver damage inducer tothe abdominal cavity of a clean mouse so as to obtain an acute different liver damage model mouse after 12-48 hours. The acute different liver damage inducer is high in application success rate, lowin condition requirements, simple in method, short in model making cycle, good in repeatability, capable of achieving evident liver damage change and capable of satisfying the requirements of liver tests.

A method of promoting spheroid formation, including: a preparation step of preparing a mixture obtained by mixing a cell sample with a promoter; and a culture step of culturing, inside a spheroid formation-culture vessel, the mixture obtained in the preparation step, in which the promoter is a polymer in which one or more selected from the group consisting of D-glucosamine, D-galactosamine, D-glucuronic acid, L-iduronic acid, and D-galactose are polymerized.

The invention discloses application of berberine hydrochloride shown as a formula (I) in preparation of a medicine used for preventing and / or treating acute hepatic failure and belongs to the field of biological medicine. According to the invention, the prevention and treatment effects of berberine hydrochloride to acute hepatic failure are inspected by building a D-galactosamine and LPS (lipopolysaccharide)-induced acute hepatic failure mouse animal model; results of experimental analysis in biology, pharmacology and molecular biology show that the effects of obviously reducing transaminase, inhibiting oxidative stress injury and inhibiting release of inflammatory factors can be realized by virtue of administration of berberine hydrochloride, and the death rate of acute hepatic failure mice can be obviously reduced, so that research results of the invention show that berberine hydrochloride can be applied to preparation of the medicine used for preventing and / or treating the acute hepatic failure. The formula (I) is described in the specification.

The invention discloses a pharmaceutical use of argininyl fructosy glucose, and belongs to the field of research and development of pharmaceutical products. The pharmaceutical use refers to application of the argininyl fructosy glucose, as an active ingredient, in preparation of drugs for treating or preventing acute hepatic failure. The acute hepatic failure is oxidative stress injury caused by the combination of lipopolysaccharide and D-galactosamine, liver cells are protected from injuries, and apoptosis caused by LPS / D-GalN is reduced. The purity of the argininyl fructosy glucose is 80-99.99%. The argininyl fructosy glucose is applied to prevention or treatment of the acute hepatic failure for the first time, so that a new raw material is provided for the preparation of the drugs for the acute hepatic failure, and a new method is also provided for the prevention and treatment of the acute liver failure.

The invention develops an anti-HBV drug, i.e., a hepatitis B granule, according to folk experience about treatment of hepatitis and the theory of traditional Chinese medicine. The hepatitis B granule is formed by combination of a plurality of Chinese herbal medicines consisting of glossy privet fruit, eclipta herba, spatholobus stem, Chinese thorowax root, red sage root, canton love-pea vine, Japanese climbing fern spore, common selfheal fruit-spike, virgate wormwood herb, European verbena herb and the like. The objective of the invention is to develop a novel natural medicinal preparation for treatment of hepatitis B. According to long-term considerable research of the inventor, the hepatitis B granule and drug serum thereof can inhibit propagation of hepatic HSC-T6 and collagen synthesis and exert obvious protection effects on acute chemical liver injury of mice caused by carbon tetrachloride, paracetamol, D-galactosamine and the like, immunological liver injury caused by concanavalin A and chronic hepatic fibrosis of rats. The hepatitis B granule provided by the invention may possibly become a novel liver protecting drug for patients with acute liver injury and chronic hepatic fibrosis. According to the invention, Guangxi characteristic crude drug resources are dug and systemized, and the novel natural medicinal preparation is provided for treatment of acute liver injury and chronic hepatic fibrosis.

The inventor discovers that Houttuynoid A has a prevention effect on mice acute liver injury induced by D-galactosamine (D-GalN) and has a prevention effect on mice acute liver injury induced by carbon tetrachloride (CCl4) through a pharmacological study. Therefore, Houttuynoid A can be utilized to prepare the medicines for preventing and treating liver injury or hepatitis. Application of Houttuynoid A on preparation of the medicine for preventing and treating liver injury provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the activity of Houttuynoid A on the treatment effect of liver injury is unexpectedly strong; and the probability that any revelation is provided by other compounds does not exist, Houttuynoid A has the excellent substantive features, and Houttuynoid A obviously has a remarkable progress when being used for preventing liver injury.

The invention relates to the field of medicines, and in particular discloses application of alantolactone in preparing a medicine for preventing liver injury, and a medicinal preparation for preventing liver injury. According to the application, treatment functions of alantolactone to liver injury are observed by using a Propionibacterium acnes, P.acnes / LPS induced mouse liver injury model and a D-galactosamine (D-GalN) induced mouse liver injury model respectively, levels of serum glutamic pyruvic transaminase and glutamic oxalacetic transaminase are analyzed, animal experiments show that the alantolactone has certain prevention and treatment functions on P.acnes / LPS and D-GalN induced acute liver injury, liver tissue injury can be alleviated, the levels of serum glutamic pyruvic transaminase and glutamic oxalacetic transaminase are effectively reduced, and the alantolactone can be used as a novel way of medicine intervention for liver injury.

The invention relates to a medicine, namely hepatitis B particles, for resisting against hepatitis B viruses. The medicine comprises a plurality of Chinese herbal medicines such as glossy privet fruits, eclipta alba, caulis spatholobi, radix bupleuri, salvia miltiorrhiza, abrus cantoniensis hance, lygodium japonicum, selfheal, oriental wormwood and verbena in a compatibility mode, and a novel Chinese herbal medicine composition for effectively treating hepatitis B is developed. Through long-term researches of the inventor, the hepatitis B particles have the obvious protection effects on mice acute chemical liver injuries caused by carbon tetrachloride, acetaminophen, D-galactosamine and the like, immunological liver injuries caused by concanavalin A and rat chronic liver fibrosis. In addition, the hepatitis B particles and drug serum of the hepatitis B particles can restrain liver HSC-T6 proliferation and collagen synthesis. By means of the medicine, a new natural liver protection medicine is possibly provided for treating acute and chronic hepatitis b, the chemical liver injuries and the hepatic fibrosis.

The invention provides an orthopedics-department adhesive containing D-galactosamine glycosylation modified mussel adhesive protein, Tween 80 and BMP-2, an adhesive kit with various components packaged separately and application. The adhesive can slowly release the BMP-2 while the basic adhesive performance is kept to achieve a good bone fracture recovery promoting effect.

The invention is a compound recipe Liuyueqing capsule (LYQC) composed of 15g of plug malan, 15g of oldenlandia diffusa, 15g of cape jasmine root, 15g of herba scutellariae barbatae, 15g of lawn pennywort herb and 15g of stringy stonecrop, which aims to provide a new effective Chinese herbal medicine composition for treating hepatitis B and solve the problem of bad hepatitis B therapeutic effect. Long term and plentiful investigations find that the LYQC can effectively protect the acute liver injuries in mice induced by carbon tetrachloride, Acetaminophen and D-Galactosamine; and can obviously restrict HBsAg and HBeAg in serum in vitro and HBV in vivo and in vitro with rather low toxicity. The investigations show that the invention can provide new medicament with good curative effect for acute viral hepatitis B and CVH chronic viral hepatitis B, hepatic fibrosis and hepatitis B virus carriers.

The invention discloses a new saponin compound with the hepatoprotective effect. The new triterpenoid saponin compound is obtained and separated from licorice root through spectrum and mass spectrometric data analysis after systematic study on chemical components of liquorice. Pharmacological experimental study shows that by utilizing the saponin compound, serum ALT, AST activity and liver tissue MDA content of CCl4 induced hepatic injury model mouse, ethyl alcohol induced hepatic injury model mouse and D-galactosamine induced hepatic injury model mouse can be obviously reduced, SOD activity of liver can be strengthened, and the saponin compound has obvious protective effect on liver injury. Toxicity experimental study shows that the new saponin compound with the hepatoprotective effect does not have significant toxicity and can be developed to a new medicine or health care product with the hepatoprotective effect.

The invention relates to the application of a Chinese traditional medicine composition in preparing medicine for preventing and curing liver injury. Pharmacological study is performed on the Chinese traditional medicine composition which is composed of 18 parts of ganltheria forrestii diels, 20 parts of elaeagnus glabra leaves, 15 parts of sambucus chinensis, 10 parts of melodinus suaveolens and 20 parts of evodia lepta to find that the Chinese medicine composition has protective effects on acute liver injury in mice induced by D-galactosamine (D-galactosamine and D-Ga1N) and CC14, and has significant progress.

The invention relates to a preparation method of Gandakang capsules, and belongs to the preparation method of traditional Chinese medicines. According to the invention, after a new process is determined, through study and dynamic detection of three batches of pilot-scale products, the character identification of the product and thin layer identification of four medical materials are determined, and an HPLC (high-performance liquid chromatography) measuring method for peoniflorin content is also built; and according to the above quality standards, the feeding process, and processing steps from the intermediate processing to finished product processing are effectively controlled in the improved production process of the Gandakang capsules, thus the product quality is guaranteed. The Gandakang capsules has the effects of obviously resisting aminotransferase increase caused by CCl4 and D-galactosamine, relieving the degree of liver injury caused by chemical substances, and protecting liver cell membrane; and the Gandakang capsules also has the effects of improving phagocytosis function of mice and the generation of antibody for mouse hemolysin caused by sheep erythrocyte, thus the product can better improve mouse immune function, and the new dosage form of Gandakang capsules has good liver protection effect and has better treatment effect if applied clinically.

The present invention relates to the technical field of liver immunology and experimental zoology, particularly to a method for establishing an acute viral hepatitis animal model, wherein D-galactosamine and polyinosinic acid:polycytidylic acid are injected in a peritoneal injection or intravenous injection manner, the D-galactosamine and the polyinosinic acid:polycytidylic acid produce the synergy effect, the ALT activity change is detected, and the acute viral hepatitis animal model is established. With the method of the present invention, the hepatitis symptoms are rapidly induced, and the viral infection simulation effect is good.

The invention conducts a pharmacological study to Aphanamgrandiol A and discovers that the Aphanamgrandiol A has the protective effect on D-galactosamine (D-Ga1N)-induced acute liver injury of mice and CC14-induced acute liver injury of mice. Therefore, the Aphanamgrandiol A can be used to prepare medicines for preventing and treating liver injury or liver injury. An application of the Aphanamgrandiol A in preparation of medicines for preventing and treating liver injury provided by the invention is disclosed for the first time. As the framework type of the Aphanamgrandiol A is a novel framework type, and the activity of the Aphanamgrandiol A to therapeutical effect of liver injury is unexpectedly strong, the probability of giving any indication by other compounds does not exist. The Aphanamgrandiol A has remarkable substantive characteristics and meanwhile has a remarkable progress for treating liver injury.

The inventor discloses 5-deoxystrigol which has a protective effect on D-galactosamine (D-GalN) induced mice acute liver injury and has a protective effect on CCl4 induced mice acute liver injury. Thus, 5-deoxystrigol can be used in preparation of medicines for preventing and treating liver injury or hepatitis and is disclosed for the first time. As the skeleton type belongs to a brand-new skeleton type and 5-deoxystrigol has strong therapeutic activity on liver injury, 5-deoxystrigol has outstanding substantial characteristics and obviously has prominent progress when used in anti-liver injury.

The invention conducts a pharmacological study to Aphanamgrandiol A and discovers that the Aphanamgrandiol A has the protective effect on D-galactosamine (D-Ga1N)-induced acute liver injury of mice and CC14-induced acute liver injury of mice. Therefore, the Aphanamgrandiol A can be used to prepare medicines for preventing and treating liver injury or liver injury. An application of the Aphanamgrandiol A in preparation of medicines for preventing and treating liver injury provided by the invention is disclosed for the first time. As the framework type of the Aphanamgrandiol A is a novel framework type, and the activity of the Aphanamgrandiol A to therapeutical effect of liver injury is unexpectedly strong, the probability of giving any indication by other compounds does not exist. The Aphanamgrandiol A has remarkable substantive characteristics and meanwhile has a remarkable progress for treating liver injury.

The invention discloses an application of Chukrasone B in the preparation of medicines for preventing and treating liver damage. The pharmacological study on the Chukrasone B shows that the Chukrasone B has a protection effect on mice acute liver injury induced by D-galactosamine (D-GalN) and CC14. Therefore, the Chukrasone B can be used for the preparation of the medicines for preventing and treating liver damage or hepatitis. The application of the Chukrasone B in the medicines for preventing and treating liver damage is disclosed by the invention for the first time. As the skeleton type of the Chukrasone B belongs to a bran-new skeleton type and the Chukrasone B has an unexpected strong activity on liver damage treatment effect, the possibility that other compounds provide revelation does not exist. The Chukrasone B has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for treating liver damage.